All In Biotech

NDA 050725 · US Antibiotics

Augmentin '400'

Amoxicillin, Clavulanate Potassium · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 31, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

918

176 Phase 3, 89 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 1, 2019.

To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium and other antibacterial drugs, Amoxicillin and Clavulanate Potassium should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin and Clavulanate Potassium is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated in the treatment of infections due to susceptible isolates of the designated bacteria in the conditions listed below*: Amoxicillin and Clavulanate Potassium is a combination penicillin-class antibacterial and beta‑lactamase inhibitor indicated for treatment of the following: Lower respiratory tract infections (1.1) Acute bacterial otitis media (1.2) Sinusitis (1.3) Skin and skin structure infections (1.4) Urinary tract infections (1.5) 1.1 Lower Respiratory Tract Infections caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . 1.2 Acute Bacterial Otitis Media caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . 1.3 Sinusitis caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . 1.4 Skin and Skin Structure Infections caused by beta‑lactamase–producing isolates of Staphylococcus aureus, Escherichia coli, and Klebsiella species. 1.5 Urinary Tract Infections caused by beta‑lactamase–producing isolates of E. coli, Klebsiella species, and Enterobacter species . 1.6 Limitations of Use When...

Mechanism: Amoxicillin and Clavulanate Potassium is an antibacterial drug. [see Microbiology 12.4 ]

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 31, 1996 Original approval · Type 3 - New Dosage Form
2 products under this application
  • AUGMENTIN '400' · AMOXICILLIN 400MG/5ML; CLAVULANATE POTASSIUM EQ 57MG BASE/5ML · FOR SUSPENSION, ORAL · Discontinued
  • AUGMENTIN '200' · AMOXICILLIN 200MG/5ML; CLAVULANATE POTASSIUM EQ 28.5MG BASE/5ML · FOR SUSPENSION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.

All 918 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,172 on PubMed

Sponsor: US Antibiotics · Also marketed as Augmentin '200'

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.